Pegaspargase

Evidence Level: L5

Predicted Indications: 7

Pegaspargase

Pharmacist Assessment Report

Pegaspargase: Chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

One-Sentence Summary

Pegaspargase is a long-acting form of the enzyme L-asparaginase, originally used to treat acute lymphoblastic leukemia (ALL). This prediction is largely label-concordant: the predicted disease is essentially the same disease family as the original indication, so it is not true repurposing.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation
TxGNN Prediction Score	0.9995
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available from DrugBank. From the analysis in the compiled data, pegaspargase is a PEGylated L-asparaginase that depletes circulating asparagine. Lymphoblasts have low asparagine synthetase activity and depend on asparagine from the blood, so depleting it selectively kills these cells.

The predicted disease (precursor B/T-cell lymphoblastic leukemia and lymphoblastic lymphoma) is the same disease family as the original ALL indication. Asparaginase-containing regimens are already a standard part of treatment, so the prediction is consistent with established use rather than a new direction.

Other predictions in the ranking are much weaker:

Lymphoid neoplasm (rank 7): mostly captures ALL and lymphoblastic lymphoma, plus NK/T-cell lymphoma. It is too heterogeneous for a single recommendation.
Hodgkin lymphoma (rank 8): the linked trials are ALL studies and the literature is about extranodal NK/T-cell lymphoma (ENKTL), a different disease. Pegaspargase is well supported in ENKTL (P-GEMOX, SMILE-type, PEG-L-CHOP, MESA regimens, including phase 2 studies), but this does not transfer to Hodgkin lymphoma. The ontology mapping appears misleading; ENKTL is worth evaluating as a separate question.
CLL/SLL variants, follicular lymphoma, cblE deficiency (ranks 2, 3, 4, 6, 9): prediction only, no trials or literature, no plausible asparagine-depletion rationale. Recommendation: Hold.
Blast phase CML (rank 10): only indirect evidence from an adult ALL trial. Recommendation: Hold.

Clinical Trial Evidence

Most relevant trials for the top prediction (the compiled data lists 35 in total):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00967057	Phase 3	Completed	470	ALLR3: international trial of re-induction chemotherapy in relapsed/refractory ALL
NCT00103285	Phase 3	Completed	5377	COG trial of chemotherapy regimens in standard-risk B-precursor ALL
NCT02003222	Phase 3	Active, not recruiting	488	Blinatumomab added to chemotherapy (including pegaspargase) in newly diagnosed BCR-ABL-negative B-ALL
NCT05602194	Phase 3	Active, not recruiting	440	Levocarnitine to prevent asparaginase-associated liver toxicity in adolescents and young adults
NCT03643276	Phase 3	Recruiting	5000	AIEOP-BFM ALL 2017 protocol for children and adolescents with ALL
NCT03914625	Phase 3	Active, not recruiting	6720	Blinatumomab plus chemotherapy (including pegaspargase) in standard-risk B-ALL and localized B-lymphoblastic lymphoma
NCT00905034	Phase 2	Completed	37	MOAD regimen (methotrexate, vincristine, pegylated asparaginase, dexamethasone) in salvage ALL
NCT00890656	Phase 2	Completed	90	Augmented hyper-CVAD in salvage ALL or lymphoblastic lymphoma
NCT01005914	Phase 2	Terminated	11	Adding PEG-asparaginase to hyper-CVAD in newly diagnosed adult ALL
NCT01403415	Phase 1	Completed	13	Temsirolimus with intensive re-induction (including pegaspargase) in relapsed ALL and non-Hodgkin lymphoma; mainly safety

Most trials test pegaspargase as part of a multi-drug backbone, so they support the regimen rather than isolating the effect of pegaspargase alone.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35271306	2022	RCT	J Clin Oncol	COG AALL1231: bortezomib in newly diagnosed T-ALL and T-lymphoblastic lymphoma
32813610	2020	RCT	J Clin Oncol	COG AALL0434: nelarabine in newly diagnosed T-ALL
27114587	2016	RCT	J Clin Oncol	AALL0232: dexamethasone and high-dose methotrexate improved outcome in high-risk B-ALL
37276451	2023	Cohort	Blood Adv	GIMEMA LAL1913: pegaspargase-modified, risk-oriented program in adult ALL
40109190	2025	Review	Haematologica	Expert consensus on preventing and managing asparaginase/pegaspargase adverse events in adults
31030380	2019	Review	Drugs	Pegaspargase in ALL: longer circulation time and less frequent dosing than native asparaginase
40858769	2025	Cohort	Ann Hematol	Pegaspargase tolerability in patients aged 55 or older treated with the LAL1913 program
34228505	2021	Other	J Clin Oncol	DFCI 11-001: efficacy and toxicity of pegaspargase vs calaspargase pegol in childhood ALL
27643446	2017	Review	Leuk Lymphoma	Hypersensitivity reactions with IV infusion vs IM injection of pegaspargase
42085640	2026	Other	Blood Adv	COG report on asparaginase toxicity during ALL induction (4925 patients aged 1–30)

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02461900	ONCASPAR	Not available	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Enzyme-based antineoplastic (asparagine depletion), used within multi-agent cytotoxic chemotherapy
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Liver function, pancreatic enzymes, triglycerides, glucose, and coagulation parameters, based on the toxicities reported in the literature
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Known toxicities reported in the literature: hypersensitivity reactions, pancreatitis, thrombosis, hepatotoxicity, hypertriglyceridemia, and hyperglycemia. Tolerability appears lower in adults aged 40–55 and older, and obesity has been linked to more toxicity.
Drug interactions: 100 interactions were found; those listed are all moderate-level. Examples include corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), antidiabetic agents (metformin, acarbose, alogliptin, canagliflozin, dapagliflozin, dulaglutide, saxagliptin), antibiotics (doxycycline, tetracycline, clarithromycin), aspirin, and bupropion. The glucose-related interactions are consistent with the hyperglycemia reported with pegaspargase.

Package insert warnings and contraindications were not available, so please refer to the Health Canada package insert for the full safety profile.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 trials and a large body of literature support asparaginase-containing regimens in lymphoblastic leukemia and lymphoma. The prediction matches the drug’s established use, so efficacy is not the main question; managing known toxicities is.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking data gap for safety screening)
Detailed mechanism of action data from DrugBank
Health Canada approved indication text, dosage form, and manufacturer for DIN 02461900
A toxicity monitoring and management plan, especially for adults aged 40 or older, patients with obesity, and patients with prior hypersensitivity
Separate evaluation of extranodal NK/T-cell lymphoma, rather than the Hodgkin lymphoma prediction, if pursuing lymphoma expansion
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.